Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Juliette Soret

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
The Lancet. Haematology|March 25, 2021
Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trialAntonio M Risitano, Alexander Röth, Juliette Soret, et al.
Annals of Hematology|February 8, 2020
Thrombocytapheresis and sequential chemotherapy for extreme symptomatic thrombocytosis secondary to myelofibrosis: a case reportPierre-Edouard Debureaux, Anne Brignier, Juliette Soret-Dulphy, et al.
Leukemia|July 11, 2023
Clinical features and genomic landscape of myeloproliferative neoplasm (MPN) patients with autoimmune and inflammatory diseases (AID)Dikelele Elessa, Lin-Pierre Zhao, Rafael Daltro de Oliveira, et al.
American Journal of Hematology|January 27, 2024
Comparative clinical and molecular landscape of primary and secondary myelofibrosis: Superior performance of MIPSS70+ v2.0 over MYSEC-PMMatteo Guerra, Hélène Pasquer, Rafael Daltro de Oliveira, et al.
Blood Advances|August 11, 2020
Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thrombosesPierre-Edouard Debureaux, Bruno Cassinat, Juliette Soret-Dulphy, et al.
JCI Insight|October 29, 2024
Comprehensive analysis of mesenchymal cells reveals a dysregulated TGF-β/WNT/HOXB7 axis in patients with myelofibrosisSaravanan Ganesan, Sarah Awan-Toor, Fabien Guidez, et al.
European Journal of Haematology|June 15, 2023
Crovalimab treatment in patients with paroxysmal nocturnal haemoglobinuria: Long-term results from the phase I/II COMPOSER trialAlexander Röth, Satoshi Ichikawa, Yoshikazu Ito, et al.
Bone Marrow Transplantation|July 6, 2021
Categorizing hematological response to eculizumab in paroxysmal nocturnal hemoglobinuria: a multicenter real-life studyPierre-Edouard Debureaux, Austin G Kulasekararaj, Fabiana Cacace, et al.
Blood|May 4, 2021
Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasmsClémence Marcault, Lin-Pierre Zhao, Nabih Maslah, et al.
Haematologica|July 9, 2026
Genetic screening of triple negative thrombocytosis patients identifies germline <i>MPL</i> compound mutations and <i>SH2B3/LNK</i> truncating mutationsBruno Cassinat, Louise Lecordier, Sarah Awan-Toor, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
The Lancet. Haematology|March 25, 2021
Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trialAntonio M Risitano, Alexander Röth, Juliette Soret, et al.
Annals of Hematology|February 8, 2020
Thrombocytapheresis and sequential chemotherapy for extreme symptomatic thrombocytosis secondary to myelofibrosis: a case reportPierre-Edouard Debureaux, Anne Brignier, Juliette Soret-Dulphy, et al.
Leukemia|July 11, 2023
Clinical features and genomic landscape of myeloproliferative neoplasm (MPN) patients with autoimmune and inflammatory diseases (AID)Dikelele Elessa, Lin-Pierre Zhao, Rafael Daltro de Oliveira, et al.
American Journal of Hematology|January 27, 2024
Comparative clinical and molecular landscape of primary and secondary myelofibrosis: Superior performance of MIPSS70+ v2.0 over MYSEC-PMMatteo Guerra, Hélène Pasquer, Rafael Daltro de Oliveira, et al.
Blood Advances|August 11, 2020
Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thrombosesPierre-Edouard Debureaux, Bruno Cassinat, Juliette Soret-Dulphy, et al.
JCI Insight|October 29, 2024
Comprehensive analysis of mesenchymal cells reveals a dysregulated TGF-β/WNT/HOXB7 axis in patients with myelofibrosisSaravanan Ganesan, Sarah Awan-Toor, Fabien Guidez, et al.
European Journal of Haematology|June 15, 2023
Crovalimab treatment in patients with paroxysmal nocturnal haemoglobinuria: Long-term results from the phase I/II COMPOSER trialAlexander Röth, Satoshi Ichikawa, Yoshikazu Ito, et al.
Bone Marrow Transplantation|July 6, 2021
Categorizing hematological response to eculizumab in paroxysmal nocturnal hemoglobinuria: a multicenter real-life studyPierre-Edouard Debureaux, Austin G Kulasekararaj, Fabiana Cacace, et al.
Blood|May 4, 2021
Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasmsClémence Marcault, Lin-Pierre Zhao, Nabih Maslah, et al.
Haematologica|July 9, 2026
Genetic screening of triple negative thrombocytosis patients identifies germline <i>MPL</i> compound mutations and <i>SH2B3/LNK</i> truncating mutationsBruno Cassinat, Louise Lecordier, Sarah Awan-Toor, et al.
Pageof 3